{
    "clinical_study": {
        "@rank": "3096", 
        "arm_group": [
            {
                "arm_group_label": "Arm I (lower-dose liposomal cytarabine-daunorubicin CPX-351)", 
                "arm_group_type": "Experimental", 
                "description": "INDUCTION/RE-INDUCTION: Patients receive lower-dose liposomal cytarabine-daunorubicin CPX-351 IV over 90 minutes on days 1, 3, and 5. Treatment repeats every 40 days for 4 courses in the absence of disease progression or unacceptable toxicity. Patients achieving CR or CRp continue on to consolidation.\nCONSOLIDATION: Patients receive lower-dose liposomal cytarabine-daunorubicin CPX-351 IV over 90 minutes on days 1 and 3. Treatment repeats every 40 days for 4 courses in the absence of disease progression or unacceptable toxicity."
            }, 
            {
                "arm_group_label": "Arm II (higher-dose liposomal cytarabine-daunorubicin CPX-351)", 
                "arm_group_type": "Experimental", 
                "description": "INDUCTION/RE-INDUCTION: Patients receive higher-dose liposomal cytarabine-daunorubicin CPX-351 IV over 90 minutes on days 1, 3, and 5. Treatment repeats every 40 days for 4 courses in the absence of disease progression or unacceptable toxicity. Patients achieving CR or CRp continue on to consolidation.\nCONSOLIDATION: Patients receive higher-dose liposomal cytarabine-daunorubicin CPX-351 IV over 90 minutes on days 1 and 3. Treatment repeats every 40 days for 4 courses in the absence of disease progression or unacceptable toxicity."
            }
        ], 
        "brief_summary": {
            "textblock": "This clinical trial studies liposomal cytarabine-daunorubicin CPX-351 in treating patients\n      with untreated myelodysplastic syndrome or acute myeloid leukemia. Drugs used in\n      chemotherapy, such as liposomal cytarabine-daunorubicin CPX-351, work in different ways to\n      stop the growth of cancer cells, either by killing the cells or by stopping them from\n      dividing."
        }, 
        "brief_title": "Liposomal Cytarabine-Daunorubicin CPX-351 in Treating Patients With Untreated Myelodysplastic Syndrome or Acute Myeloid Leukemia", 
        "condition": [
            "Adult Acute Megakaryoblastic Leukemia (M7)", 
            "Adult Acute Monoblastic Leukemia (M5a)", 
            "Adult Acute Monocytic Leukemia (M5b)", 
            "Adult Acute Myeloblastic Leukemia With Maturation (M2)", 
            "Adult Acute Myeloblastic Leukemia Without Maturation (M1)", 
            "Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities", 
            "Adult Acute Myeloid Leukemia With Del(5q)", 
            "Adult Acute Myeloid Leukemia With Inv(16)(p13;q22)", 
            "Adult Acute Myeloid Leukemia With t(16;16)(p13;q22)", 
            "Adult Acute Myeloid Leukemia With t(8;21)(q22;q22)", 
            "Adult Acute Myelomonocytic Leukemia (M4)", 
            "Adult Erythroleukemia (M6a)", 
            "Adult Pure Erythroid Leukemia (M6b)", 
            "de Novo Myelodysplastic Syndromes", 
            "Secondary Acute Myeloid Leukemia", 
            "Untreated Adult Acute Myeloid Leukemia"
        ], 
        "condition_browse": {
            "mesh_term": [
                "Congenital Abnormalities", 
                "Leukemia", 
                "Leukemia, Erythroblastic, Acute", 
                "Leukemia, Megakaryoblastic, Acute", 
                "Leukemia, Monocytic, Acute", 
                "Leukemia, Myeloid, Acute", 
                "Leukemia, Myeloid", 
                "Leukemia, Myelomonocytic, Acute", 
                "Myelodysplastic Syndromes", 
                "Preleukemia", 
                "Leukemia, Myelomonocytic, Chronic"
            ]
        }, 
        "detailed_description": {
            "textblock": "PRIMARY OBJECTIVES:\n\n      I. Estimate whether the 32 units/m^2 or the 64 units/m^2 or both dose levels of CPX-351\n      (liposomal cytarabine-daunorubicin CPX-351) are likely to improve treatment-related\n      mortality (TRM) rate while keeping the complete remission (CR) rate constant in patients\n      with untreated high-risk myelodysplastic syndrome (MDS) or non-acute promyelocytic leukemia\n      (APL) acute myeloid leukemia (AML) at high risk of TRM.\n\n      SECONDARY OBJECTIVES:\n\n      I. Describe the CR/CR with incomplete platelet count recovery (CRp) rate after up to 4\n      cycles of induction/re-induction therapy.\n\n      II. Describe the event-free survival, disease-free survival, and overall survival of\n      patients who achieve CR/CRp.\n\n      III. Estimate the frequency and severity of regimen-associated toxicities.\n\n      OUTLINE: Patients are randomized to 1 of 2 treatment arms.\n\n      ARM I:\n\n      INDUCTION/RE-INDUCTION: Patients receive lower-dose liposomal cytarabine-daunorubicin\n      CPX-351 intravenously (IV) over 90 minutes on days 1, 3, and 5. Treatment repeats every 40\n      days for 4 courses in the absence of disease progression or unacceptable toxicity. Patients\n      achieving CR or CRp continue on to consolidation.\n\n      CONSOLIDATION: Patients receive lower-dose liposomal cytarabine-daunorubicin CPX-351 IV over\n      90 minutes on days 1 and 3. Treatment repeats every 40 days for 4 courses in the absence of\n      disease progression or unacceptable toxicity.\n\n      ARM II:\n\n      INDUCTION/RE-INDUCTION: Patients receive higher-dose liposomal cytarabine-daunorubicin\n      CPX-351 IV over 90 minutes on days 1, 3, and 5. Treatment repeats every 40 days for 4\n      courses in the absence of disease progression or unacceptable toxicity. Patients achieving\n      CR or CRp continue on to consolidation.\n\n      CONSOLIDATION: Patients receive higher-dose liposomal cytarabine-daunorubicin CPX-351 IV\n      over 90 minutes on days 1 and 3. Treatment repeats every 40 days for 4 courses in the\n      absence of disease progression or unacceptable toxicity.\n\n      After completion of study treatment, patients are followed up for 1 month."
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Diagnosis of untreated \"high-risk\" MDS (>= 10% blasts) or AML other than APL with\n             t(15;17)(q22;q12) or variants according to the 2008 World Health Organization (WHO)\n             classification; patients with biphenotypic AML are eligible; outside diagnostic\n             material is acceptable as long as peripheral blood and/or bone marrow slides are\n             reviewed at the study institution and cytogenetic/molecular information is available\n\n               -  Prior hydroxyurea for AML is permitted but should be discontinued prior to start\n                  of CPX-351 treatment\n\n               -  Azacitidine, decitabine, lenalidomide, and growth factors are permitted for\n                  low-risk MDS (< 10% blasts); all treatments for MDS should be discontinued prior\n                  to start of CPX-351 treatment\n\n          -  Treatment-related mortality (TRM) score >= 13.1 as calculated with simplified model\n\n          -  Bilirubin < 2.0 mg/mL x upper limit of normal; this requirement reflects the\n             excretion of CPX-351 by the liver\n\n          -  Aspartate aminotransferase (AST)/alanine aminotransferase (ALT) < 4.0 x upper limit\n             of normal; this requirement reflects the excretion of CPX-351 by the liver\n\n          -  Left ventricular ejection fraction (LVEF) >= 40%, assessed within 28 days prior to\n             registration, e.g. by multi gated acquisition scan (MUGA) scan or echocardiography,\n             or other appropriate diagnostic modality\n\n          -  Patients with symptoms/signs of hyperleukocytosis or white blood cell (WBC) >\n             100,000/uL can be treated with leukapheresis prior to enrollment\n\n          -  Provide signed written informed consent\n\n        Exclusion Criteria:\n\n          -  Refractory/relapsing blast crisis of chronic myelogenous leukemia (CML)\n\n          -  Concomitant illness associated with a likely survival of < 1 year\n\n          -  Active systemic fungal, bacterial, viral, or other infection, unless under treatment\n             with anti-microbials and controlled/stable, as defined as being afebrile and\n             hemodynamically stable for 24-48 hours"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "90", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "March 1, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01804101", 
            "org_study_id": "2642.00", 
            "secondary_id": [
                "NCI-2013-00481", 
                "2642.00", 
                "P30CA015704"
            ]
        }, 
        "intervention": {
            "arm_group_label": [
                "Arm I (lower-dose liposomal cytarabine-daunorubicin CPX-351)", 
                "Arm II (higher-dose liposomal cytarabine-daunorubicin CPX-351)"
            ], 
            "description": "Given IV", 
            "intervention_name": "liposomal cytarabine-daunorubicin CPX-351", 
            "intervention_type": "Drug", 
            "other_name": "CPX-351"
        }, 
        "intervention_browse": {
            "mesh_term": [
                "Cytarabine", 
                "Daunorubicin"
            ]
        }, 
        "is_fda_regulated": "Yes", 
        "is_section_801": "No", 
        "lastchanged_date": "December 17, 2013", 
        "location": [
            {
                "contact": {
                    "last_name": "Bruno C. de Medeiros", 
                    "phone": "650-725-3973"
                }, 
                "facility": {
                    "address": {
                        "city": "Stanford", 
                        "country": "United States", 
                        "state": "California", 
                        "zip": "94305"
                    }, 
                    "name": "Stanford University Medical Center"
                }, 
                "investigator": {
                    "last_name": "Bruno C. de Medeiros", 
                    "role": "Principal Investigator"
                }, 
                "status": "Recruiting"
            }, 
            {
                "contact": {
                    "last_name": "B. D. Smith", 
                    "phone": "410-614-5068"
                }, 
                "facility": {
                    "address": {
                        "city": "Baltimore", 
                        "country": "United States", 
                        "state": "Maryland", 
                        "zip": "21287-8936"
                    }, 
                    "name": "Johns Hopkins University"
                }, 
                "investigator": {
                    "last_name": "B. D. Smith", 
                    "role": "Principal Investigator"
                }, 
                "status": "Recruiting"
            }, 
            {
                "contact": {
                    "last_name": "Roland B. Walter", 
                    "phone": "206-667-3599"
                }, 
                "facility": {
                    "address": {
                        "city": "Seattle", 
                        "country": "United States", 
                        "state": "Washington", 
                        "zip": "98109"
                    }, 
                    "name": "Fred Hutchinson Cancer Research Center/University of Washington Cancer Consortium"
                }, 
                "investigator": {
                    "last_name": "Roland B. Walter", 
                    "role": "Principal Investigator"
                }, 
                "status": "Recruiting"
            }
        ], 
        "location_countries": {
            "country": "United States"
        }, 
        "number_of_arms": "2", 
        "official_title": "Liposomal Cytarabine and Daunorubicin (CPX-351) for Adults With Untreated High-Risk MDS and Non-APL AML at High Risk of Treatment-Related Mortality", 
        "overall_official": {
            "affiliation": "Fred Hutchinson Cancer Research Center/University of Washington Cancer Consortium", 
            "last_name": "Roland Walter", 
            "role": "Principal Investigator"
        }, 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": "United States: Food and Drug Administration", 
            "has_dmc": "No"
        }, 
        "phase": "N/A", 
        "primary_completion_date": {
            "#text": "June 2016", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": [
            {
                "measure": "CR rate", 
                "safety_issue": "No", 
                "time_frame": "Up to 1 month after completion of study treatment"
            }, 
            {
                "measure": "TRM rate", 
                "safety_issue": "Yes", 
                "time_frame": "Up to day 28"
            }
        ], 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01804101"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "source": "Fred Hutchinson Cancer Research Center", 
        "sponsors": {
            "collaborator": {
                "agency": "National Cancer Institute (NCI)", 
                "agency_class": "NIH"
            }, 
            "lead_sponsor": {
                "agency": "Fred Hutchinson Cancer Research Center", 
                "agency_class": "Other"
            }
        }, 
        "start_date": "April 2013", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "December 2013"
    }
}